You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic Review
|
|---|---|
| Published in |
Cancer Epidemiology, Biomarkers & Prevention, November 2013
|
| DOI | 10.1158/1055-9965.epi-13-0298 |
| Pubmed ID | |
| Authors |
Jennifer M. Gierisch, Remy R. Coeytaux, Rachel Peragallo Urrutia, Laura J. Havrilesky, Patricia G. Moorman, William J. Lowery, Michaela Dinan, Amanda J. McBroom, Vic Hasselblad, Gillian D. Sanders, Evan R. Myers |
| Abstract |
Oral contraceptives may influence the risk of certain cancers. As part of the AHRQ Evidence Report, Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer, we conducted a systematic review to estimate associations between oral contraceptive use and breast, cervical, colorectal, and endometrial cancer incidence. We searched PubMed, Embase, and Cochrane Database of Systematic Reviews. Study inclusion criteria were women taking oral contraceptives for contraception or ovarian cancer prevention; includes comparison group with no oral contraceptive use; study reports quantitative associations between oral contraceptive exposure and relevant cancers; controlled study or pooled patient-level meta-analyses; sample size for nonrandomized studies ≥100; peer-reviewed, English-language; published from January 1, 2000 forward. Random-effects meta-analyses were conducted by estimating pooled ORs with 95% confidence intervals (CIs). We included 44 breast, 12 cervical, 11 colorectal, and 9 endometrial cancers studies. Breast cancer incidence was slightly but significantly increased in users (OR, 1.08; CI, 1.00-1.17); results show a higher risk associated with more recent use of oral contraceptives. Risk of cervical cancer was increased with duration of oral contraceptive use in women with human papillomavirus infection; heterogeneity prevented meta-analysis. Colorectal cancer (OR, 0.86; CI, 0.79-0.95) and endometrial cancer incidences (OR, 0.57; CI, 0.43-0.77) were significantly reduced by oral contraceptive use. Compared with never use, ever use of oral contraceptives is significantly associated with decreases in colorectal and endometrial cancers and increases in breast cancers. Although elevated breast cancer risk was small, relatively high incidence of breast cancers means that oral contraceptives may contribute to a substantial number of cases. |
X Demographics
The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 6% |
| Spain | 1 | 6% |
| Namibia | 1 | 6% |
| Canada | 1 | 6% |
| Unknown | 12 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 88% |
| Scientists | 1 | 6% |
| Practitioners (doctors, other healthcare professionals) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 503 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Turkey | 1 | <1% |
| United Kingdom | 1 | <1% |
| Egypt | 1 | <1% |
| Sri Lanka | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 498 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 86 | 17% |
| Student > Master | 67 | 13% |
| Researcher | 49 | 10% |
| Student > Ph. D. Student | 45 | 9% |
| Student > Doctoral Student | 33 | 7% |
| Other | 84 | 17% |
| Unknown | 139 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 175 | 35% |
| Biochemistry, Genetics and Molecular Biology | 36 | 7% |
| Nursing and Health Professions | 30 | 6% |
| Agricultural and Biological Sciences | 28 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 3% |
| Other | 57 | 11% |
| Unknown | 163 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 133. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 April 2024.
All research outputs
#318,676
of 25,718,113 outputs
Outputs from Cancer Epidemiology, Biomarkers & Prevention
#116
of 4,864 outputs
Outputs of similar age
#2,444
of 228,270 outputs
Outputs of similar age from Cancer Epidemiology, Biomarkers & Prevention
#5
of 56 outputs
Altmetric has tracked 25,718,113 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,864 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.6. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,270 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 56 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.